Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targ...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Derek K., Oni, Tobiloba E., Thalappillil, Jennifer S., Park, Youngkyu, Ting, Hsiu-Chi, Alagesan, Brinda, Prasad, Nadia V., Addison, Kenneth, Rivera, Keith D., Pappin, Darryl J., Van Aelst, Linda, Tuveson, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166058/
https://www.ncbi.nlm.nih.gov/pubmed/34021083
http://dx.doi.org/10.1073/pnas.2016904118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166058/
https://www.ncbi.nlm.nih.gov/pubmed/34021083
http://dx.doi.org/10.1073/pnas.2016904118

Ejemplares similares